, L. et al., International J. of
Pharmaceutics, 114, 141-149, (1995).
12. Perrin, J.H. and Saunders, L., Biochim. Biophys.
Acta., 84, 216-217 (1964).
13. Hayashi, H. et
, L. et al., International J. of
Pharmaceutics, 114, 141-149, (1995).
12. Perrin, J.H. and Saunders, L., Biochim. Biophys.
Acta., 84, 216-217 (1964).
13. Hayashi, H. et
, L. et al., International J. of
Pharmaceutics, 114, 141-149, (1995).
12. Perrin, J.H. and Saunders, L., Biochim. Biophys.
Acta., 84, 216-217 (1964).
13. Hayashi, H. et
, L. et al., International J. of
Pharmaceutics, 114, 141-149, (1995).
12. Perrin, J.H. and Saunders, L., Biochim. Biophys.
Acta., 84, 216-217 (1964).
13. Hayashi, H. et
, L. et al., International J. of
Pharmaceutics, 114, 141-149, (1995).
12. Perrin, J.H. and Saunders, L., Biochim. Biophys.
Acta., 84, 216-217 (1964).
13. Hayashi, H. et
, L. et al., International J. of
Pharmaceutics, 114, 141-149, (1995).
12. Perrin, J.H. and Saunders, L., Biochim. Biophys.
Acta., 84, 216-217 (1964).
13. Hayashi, H. et
, L. et al., International J. of
Pharmaceutics, 114, 141-149, (1995).
12. Perrin, J.H. and Saunders, L., Biochim. Biophys.
Acta., 84, 216-217 (1964).
13. Hayashi, H. et
, L. et al., International J. of
Pharmaceutics, 114, 141-149, (1995).
12. Perrin, J.H. and Saunders, L., Biochim. Biophys.
Acta., 84, 216-217 (1964).
13. Hayashi, H. et
Hovgaard, L. et al., International J. of
Pharmaceutics, 114, 141-149, (1995).
12. Perrin, J.H. and Saunders, L., Biochim. Biophys.
Acta., 84, 216-217 (1964).
13. Hayashi, H. et al., Chemistry Letters
, L. et al., International J. of
Pharmaceutics, 114, 141-149, (1995).
12. Perrin, J.H. and Saunders, L., Biochim. Biophys.
Acta., 84, 216-217 (1964).
13. Hayashi, H. et
, L. et al., International J. of
Pharmaceutics, 114, 141-149, (1995).
12. Perrin, J.H. and Saunders, L., Biochim. Biophys.
Acta., 84, 216-217 (1964).
13. Hayashi, H. et
, L. et al., International J. of
Pharmaceutics, 114, 141-149, (1995).
12. Perrin, J.H. and Saunders, L., Biochim. Biophys.
Acta., 84, 216-217 (1964).
13. Hayashi, H. et
, L. et al., International J. of
Pharmaceutics, 114, 141-149, (1995).
12. Perrin, J.H. and Saunders, L., Biochim. Biophys.
Acta., 84, 216-217 (1964).
13. Hayashi, H. et
, L. et al., International J. of
Pharmaceutics, 114, 141-149, (1995).
12. Perrin, J.H. and Saunders, L., Biochim. Biophys.
Acta., 84, 216-217 (1964).
13. Hayashi, H. et
abdominal area, front legs, hind legs and tail/perianal
area. The maximum total possible score was 216.
Impression smears or acetate tape preparations were examined
from two different affected areas
hydroxyapatite, can also be used to make composite GelMA bioinks
with tuned mechanical properties.216–219 In addition, multi-walled
carbon nanotubes (MWCNTs) have also been added to GelMA to
enhance
hydroxyapatite, can also be used to make composite GelMA bioinks
with tuned mechanical properties.216–219 In addition, multi-walled
carbon nanotubes (MWCNTs) have also been added to GelMA to
enhance
DAP Kinase 2 D3191 23604, 13143, 300799 DAPK2,Dapk2 NP_055141.2,NP_034149.2,NP_001013127.1 P y y y
216 Anti Cy3+Cy5 C0992
217 Daxx D7810 13163, 1616 DAXX,Daxx NP_031855.3,NP_001341.1 P y n/d n/d
218 DcR1
DAP Kinase 2 D3191 23604, 13143, 300799 DAPK2,Dapk2 NP_055141.2,NP_034149.2,NP_001013127.1 P y y y
216 Anti Cy3+Cy5
217 Daxx D7810 13163, 1616 DAXX,Daxx NP_031855.3,NP_001341.1 P y n/d n/d
218 DcR1 D3566